Preliminary Evaluation of Intrinsic IB Spot Serum or Gel (Cryosim-1) in Dialysis Patients with Chronic Kidney Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011257

Enrollment

Registered

2025-12-05

Start date

2024-11-06

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Intrinsic IB spot serum/gel or Vehicle only serum/gel Apply topically to target lesions whenever itches for two weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Age =20 years 2.Patients with chronic kidney disease on dialysis 3.Able to comply and provide IRB(Institution Review Board)-approved written consent. 4.not included in the exclusion criteria 5.Patients who understands the contents of the clinical trial, is cooperative, and is determined to be able to participate by the end of the clinical trial 6.Able to follow up during study period

Exclusion criteria

Exclusion criteria: 1.Active clinically significant infection. 2.Pregnancy or breastfeeding. 3.Any condition judged by investigator to make participation unsafe or impracticable.

Design outcomes

Primary

Measure	Time frame
Between-group difference ((Intrinsic IB spot serum/gel or Vehicle serum/gel) in change ) in VAS(Visual analogue scale)	—

Secondary

Measure	Time frame
Between-group difference ((Intrinsic IB spot serum/gel or Vehicle serum/gel) in change) in Pruritus Scale(5-D score) and DLQI(Dermatology Life Quality Index)	—

Countries

Korea, Republic of

Contacts

Public ContactHyeOne KIM

Hallym University Medical Center-Kangnam

hyeonekim@gmail.com+82-2-829-5221

Outcome results